Stocktwits125d agoneutral
IBRX Stock Slips Overnight: Insider Sale Tests Retail Optimism Ahead Of FDA Growth CatalystNews
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
105last 24h
3127last 7d
510● bullish (7d)
311● bearish (7d)
227publishers
Insider Monkey142d agoneutral
Jim Cramer Says “Let ImmunityBio Be Your Speculation” to a CallerInsider Monkey151d agoneutral
ImmunityBio (IBRX): One of the Best Performing Growth Stocks So Far in 2026Insider Monkey156d agobullish
ImmunityBio Inc. (IBRX): One of the Most Shorted Mid-Cap Stocks to Buy NowSimply Wall St.158d agoneutral
ImmunityBio ASCO ANKTIVA Data Reframes Lung And Bladder Cancer OutlookInsider Monkey163d agoneutral
ImmunityBio (IBRX) Health Economic Analysis Highlights ANKTIVA Value Over TAR-200Simply Wall St.164d agoneutral
ANKTIVA Label Expansion Bid in Papillary NMIBC Could Be A Game Changer For ImmunityBio (IBRX)Insider Monkey164d agobullish
Is ImmunityBio Inc. (IBRX) One of the Best Momentum Stocks to Buy According to Analysts?Simply Wall St.172d agoneutral
Assessing ImmunityBio (IBRX) Valuation After FDA Approval For Anktiva And Share Price CooldownBenzinga173d agobullish
ImmunityBio Expands Bladder Cancer Arsenal With Exclusive Japanese BCG PartnershipInvestorsHub174d agoneutral
ImmunityBio Shares Rise After Securing Five New U.S. Patents for Bladder Cancer Therapy (IBRX)